Clinical Trials Directory

Trials / Conditions / Stage IV Salivary Gland Cancer

Stage IV Salivary Gland Cancer

19 registered clinical trials studyying Stage IV Salivary Gland Cancer.

StatusTrialSponsorPhase
TerminatedPaclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
NCT01249443
AIDS Malignancy ConsortiumPhase 1
TerminatedPhase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
NCT01283178
Virginia Commonwealth UniversityPhase 1
CompletedTLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam
NCT01334177
University of WashingtonPhase 1
CompletedCarboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr
NCT01316757
Fox Chase Cancer CenterPhase 2
CompletedL-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For
NCT01155609
University of WashingtonN/A
CompletedCapecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
NCT01044433
Abramson Cancer Center at Penn MedicinePhase 2
TerminatedSunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C
NCT00906360
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri
NCT00492089
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne
NCT00101348
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedAlvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00089362
National Cancer Institute (NCI)Phase 1
CompletedBortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Ad
NCT00077428
National Cancer Institute (NCI)Phase 2
TerminatedIntratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the
NCT00081211
National Cancer Institute (NCI)Phase 1
CompletedErlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca
NCT00055770
National Cancer Institute (NCI)Phase 1 / Phase 2
Completed7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid
NCT00031681
National Cancer Institute (NCI)Phase 1
CompletedErlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498
National Cancer Institute (NCI)Phase 1
CompletedVaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT00028496
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and
NCT00023959
National Cancer Institute (NCI)Phase 1
CompletedInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
National Cancer Institute (NCI)Phase 1